Table 1. Patient Demographic and Clinical Characteristics.
| Factor | Treatment, n(%) |
|||
|---|---|---|---|---|
| Total n = 97(%) | Icotinib+RT n = 56(%) | Icotinib alone n = 41(%) | P value | |
| Age at BM diagnosis (year) | ||||
| Median age | 58 | 56 | 59 | |
| <60 | 55 (57) | 36 (64) | 19 (46) | |
| ≥60 | 42 (43) | 20 (36) | 22 (54) | 0.78 |
| Sex | ||||
| Male | 43 (44) | 22 (39) | 21 (51) | |
| Female | 54 (56) | 34 (61) | 20 (49) | 0.24 |
| Smoking history | ||||
| Never-smoker | 66 (68) | 40 (71) | 26 (63) | |
| ≤10 | 8 (8) | 4 (7) | 4 (10) | |
| >10 | 23 (24) | 12 (22) | 11 (27) | 0.70 |
| Symptomatic from BM | ||||
| No | 71 (73) | 35 (63) | 36 (88) | |
| Yes | 26 (27) | 21 (37) | 5 (12) | 0.005 |
| Brain metastasis at time of diagnosis | ||||
| No | 21 (22) | 13 (23) | 8 (20) | |
| Yes | 76 (78) | 43 (77) | 33 (80) | 0.66 |
| NO. of brain metastases at first imaging | ||||
| 1′ | 37 (38) | 17 (30) | 20 (49) | |
| 2–3′ | 13 (13) | 6 (11) | 7 (17) | |
| ≥4 | 47 (49) | 33 (59) | 14 (34) | 0.054 |
| Extracranial metastasis present | ||||
| Yes | 71 (73) | 34 (61) | 37 (90) | |
| No | 26 (27) | 22 (39) | 4 (10) | 0.003 |
| Graded prognostic assessment | ||||
| 0.0–2.0 | 72 (74) | 42 (75) | 30 (73) | |
| 2.5–4.0 | 25 (26) | 14 (25) | 11 (27) | 0.84 |
| EGFR mutation | ||||
| Exon 19 deletion | 57 (59) | 34 (61) | 23 (56) | |
| Exon 21 L858 R | 40 (41) | 22 (39) | 18 (44) | 0.65 |
| KPS | ||||
| 90 | 40 (41) | 24 (43) | 16 (39) | |
| 70–80 | 45 (46) | 27 (48) | 18 (44) | |
| <70 | 12 (13) | 5 (9) | 7 (17) | 0.49 |